Vedolizumab
A biologic that stops certain immune cells moving into the gut wall. Given by drip or injection.
Also called: entyvio, vedo, vedolizamab, anti-integrin, integrin inhibitor
Related words biologic
A biologic that stops certain immune cells moving into the gut wall. Given by drip or injection.
Also called: entyvio, vedo, vedolizamab, anti-integrin, integrin inhibitor
Related words biologic
Crohn's & Colitis UK explains that biologics are antibody medicines made by living cells in a lab. Each one targets a specific part of the immune system involved in inflammation: anti-TNFs (infliximab, adalimumab), the anti-integrin vedolizumab, and interleukin blockers (ustekinumab, risankizumab, mirikizumab, guselkumab). They are given by drip or by injection under the skin. Upadacitinib is a 'targeted' tablet, not a biologic.
Sources
NICE still recommends vedolizumab (Entyvio) after an anti-TNF has failed or is unsuitable, and a Cochrane review found it works better than placebo. However, the 2025 BSG guideline no longer routinely suggests it for moderate to severe Crohn's, because the effect seen in trials was small. The review of the guideline says it may still suit selected people, after discussion with the IBD team.
Sources
NICE has approved infliximab and adalimumab (TA187), vedolizumab (TA352), ustekinumab (TA456), risankizumab (TA888), upadacitinib (TA905), mirikizumab (TA1080) and guselkumab (TA1095) for Crohn's, each under certain conditions. Most of the newer ones are for people whose disease has not responded to, or cannot have, an earlier treatment. Your IBD team decides with you which is suitable.
Sources
Cochrane reviews are systematic reviews: researchers find every good trial on a question, judge how reliable each one is and combine the results. They also grade how certain the evidence is. For Crohn's, Cochrane has found strong evidence for some treatments, such as vedolizumab, and too little evidence to judge others, such as treatments for fatigue.
Sources
There is no single best biologic for everyone. Trials comparing two drugs directly are still few: SEAVUE found ustekinumab and adalimumab worked about equally well in people new to biologics, and SEQUENCE found risankizumab was better than ustekinumab at healing the bowel in people for whom anti-TNF drugs had not worked. A 2026 Cochrane review comparing all the options says more head-to-head trials are needed.
Sources
A guide to vedolizumab (Entyvio), which starts as a drip into a vein and may later be switched to injections under the skin. It covers how it works on the gut, trial results and side effects.
Topics Biologics and newer medicines
Jargon explained integrin intravenous infusion subcutaneous injection
NICE's appraisal recommending vedolizumab (Entyvio) for adults with moderate to severe Crohn's disease when an anti-TNF medicine has failed, stopped working or is unsuitable. It is given as a planned course and reassessed at 12 months.
Topics Biologics and newer medicines Medicines
Jargon explained anti-TNF TNF-alpha inhibitor patient access scheme moderately to severely active
Pooling several trials, Cochrane found high-certainty evidence that vedolizumab (Entyvio) works better than placebo both for bringing on remission and keeping it. Overall side effects were probably similar to placebo. Head-to-head comparisons with other biologics are still needed.
Topics Biologics and newer medicines Research
Jargon explained high-certainty evidence induction maintenance integrin
The main trial of vedolizumab (Entyvio) in Crohn's. It helped more people reach remission than placebo by week 6, and people who responded and stayed on it were more likely to be in remission at one year. Side effects, including infections, were somewhat more common than on placebo in this trial.
Topics Biologics and newer medicines
Jargon explained integrin induction maintenance serious adverse event
An NIHR-funded Cochrane review that compares all the biologic and newer drugs for Crohn's at once, even where they were never tested against each other directly. Many, including adalimumab, risankizumab, guselkumab, upadacitinib and vedolizumab, were probably or possibly better than placebo, but the strength of evidence varied a lot. The authors say more head-to-head trials, more focus on bowel healing, and better long-term safety data are needed.
Topics Biologics and newer medicines Research
Jargon explained network meta-analysis relative risk number needed to treat biosimilar
NICE's appraisal allowing guselkumab (Tremfya) for adults with moderate to severe Crohn's disease when earlier treatment has not worked or cannot be tolerated and an anti-TNF medicine is not working or unsuitable. It asks clinicians to choose the least expensive of the suitable options, which include guselkumab, risankizumab and vedolizumab.
Topics Biologics and newer medicines Medicines
Jargon explained IL-23 inhibitor TNF-alpha inhibitor conventional treatment
A readable summary of what the 2025 BSG guideline says about Crohn's. Key points: early 'top-down' infliximab with an immunomodulator for moderate to severe disease; avoiding long or repeated steroid courses; no longer suggesting immunomodulators alone; upadacitinib and risankizumab added; vedolizumab no longer routinely suggested; drug-level testing for anti-TNFs; early surgery as an option for limited ileocaecal disease; and offering early treatment after resection.
Topics Medicines Surgery Monitoring
Jargon explained top-down step-up therapeutic drug monitoring ileocaecal resection Rutgeerts score immunogenicity
NICE's appraisal recommending ustekinumab (Stelara) for adults with moderate to severe Crohn's disease when standard treatment or an anti-TNF medicine has not worked, stopped working or cannot be used. It says the choice between biologics should be made with the patient, using the cheapest suitable option.
Topics Biologics and newer medicines Medicines
Jargon explained interleukin inhibitor TNF-alpha inhibitor biological therapy
NHS England's page on biosimilars: biological medicines shown to have no meaningful differences in quality, safety or effectiveness from the original brand. It explains why the NHS encourages their use, that switching between the original and a biosimilar is now accepted practice, and how savings are reinvested.
Topics Biologics and newer medicines Medicines
Jargon explained biosimilar originator medicine switching
NICE's appraisal recommending risankizumab (Skyrizi) for people aged 16 and over with moderate to severe Crohn's disease after a previous biologic has failed or was not tolerated, or when anti-TNF medicines are unsuitable.
Topics Biologics and newer medicines Medicines
Jargon explained IL-23 inhibitor TNF-alpha inhibitor biological treatment
An overview of biologics and other targeted medicines for Crohn's and Colitis, with a table of each medicine, its brand names and how it works. It explains that biologics are lab-made antibodies given by drip or injection, and covers biosimilars, anti-TNFs, interleukin inhibitors and JAK inhibitors.
Topics Biologics and newer medicines Medicines
Jargon explained biologic biosimilar anti-TNF IL-23 inhibitor JAK inhibitor advanced therapy
A guide to infliximab, an anti-TNF biologic given by drip or as an injection under the skin. It lists the original brand Remicade and biosimilars such as Remsima, Inflectra, Flixabi and Zessly, and explains checks before starting, that your team may measure drug and antibody levels in your blood, and possible side effects.
Topics Biologics and newer medicines Monitoring
Jargon explained anti-TNF infusion subcutaneous biosimilar drug levels antibodies